author-photo

Deric M Park

University of Chicago

15

Papers

74

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.

2021 Oncologist
Show All
- Source
- Cite
- Save
Citations (4)
TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma.

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (2)
An atypical presentation of primary central nervous system lymphoma: A case report.

2020 Medicine
Show All
- Source
- Cite
- Save
Citations (0)
NCMP-18. NEUROTOXICITY AS A POTENTIAL SURROGATE MARKER FOR THERAPEUTIC RESPONSE WITH COMMERCIAL ANTI-CD19 CAR T-CELL THERAPY

2020 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
CTNI-02. TBCRC049: A PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF TUCATINIB, TRASTUZUMAB AND CAPECITABINE FOR THE TREATMENT OF LEPTOMENINGEAL METASTASIS IN HER2 POSITIVE BR1AST CANCER

2020 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy.

2020 Immunotherapy
Show All
- Source
- Cite
- Save
Citations (0)
A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
IMMU-51. NEUROLOGIC IMMUNE-RELATED ADVERSE EVENTS MIMICS, RISK FACTORS, AND MECHANISMS: CLIPPERS AND ASEPTIC MENINGITIS

2020 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
CAR-T-cell-Related Encephalopathy Syndrome: High Rates of Neurotoxicity in Clinical Practice (P1.6-007)

2019 Neurology
Show All
- Source
- Cite
- Save
Citations (0)
NCMP-08. CLINICAL FEATURES OF CAR T-CELL THERAPY NEUROTOXICITY AS POTENTIAL SURROGATE MARKERS FOR PROGRESSION AND OUTCOME

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)